20-577 Phase I
A First-in-human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors (View details on clinicaltrial.gov)
Safe Care CommitmentGet the latest news on COVID-19, the vaccine and care at Mass General.Learn more
A First-in-human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors (View details on clinicaltrial.gov)
A Phase 1 Study of LY3410738 Administered to Patients with Advanced Solid Tumors with IDH1 Mutations (View details on clinicaltrial.gov)
A Phase 1, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0022, a novel MET/CSF1R/SRC inhibitor, in Patients with Advanced Solid Tumors Harboring Genetic Alterations in MET (View details on clinicaltrial.gov)
A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation (View details on clinicaltrial.gov)
A pilot study of neoadjuvant stereotactic beam radiation therapy followed by atezolizumab and bevacizumab in resectable hepatocellular carcinoma (View details on clinicaltrial.gov)
A prospective, multicenter, open-label single arm study evaluating the safety and efficacy of selective internal radiation therapy (SIRT) using SIR-Spheres® Y-90 resin microspheres on duration of response (DoR) and objective response rate (ORR) in unresectable hepatocellular carcinoma (HCC) patients (DOORwaY90 Study) (View details on clinicaltrial.gov)
NRG-GI003: A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma (View details on clinicaltrial.gov)
Phase IB Study of Atezolizumab and Bevacizumab with SBRT for Unresectable Hepatocellular Carcinoma (View details on clinicaltrial.gov)